> Skip repeated content

HSS Checkpoint Inhibitor-Associated Immune Related Adverse Events Registry

IRB Number: 2017-1898

July 21, 2021

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Karmela Kim Chan, MD


Anne R. Bass, MD
Vivian Bykerk, MD
Susan Goodman, MD



This is a registry, without any intervention.

Inclusion/Exclusion Criteria

Patients who are referred to HSS rheumatology for mangement of adverse events arising from cancer immunotherapy are elibible for enrollment into the registry.

Contact Information

Diviya Rajesh